Press releaseGlobe Newswire
LB Pharmaceuticals
LBRX · NASDAQ
$41.00+$2.19 (+5.64%)TodayMarket closed ·
Prev close $38.81
Latest news
- Press releaseGlobe Newswire
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
- Press releaseGlobe Newswire
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
- Press releaseGlobe Newswire
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
- Press releaseGlobe Newswire
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
LB Pharmaceuticals Announces $150 Million Private Placement
- Press releaseGlobe Newswire
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
- Press releaseGlobe Newswire
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
- Press releaseGlobe Newswire
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
- Press releasePRNewswire
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
- NewsAvi Kapoor
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
- NewsAvi Kapoor
This Commerce Bancshares Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.